Transcode Therapeutics Faces Delisting Concerns

TL;DR

Transcode Therapeutics is on the chopping block for delisting.

AI Summary

Transcode Therapeutics, Inc. filed an 8-K on September 27, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The earliest event reported was on September 23, 2024. The company is incorporated in Delaware and its principal executive offices are located in Boston, Massachusetts.

Why It Matters

This filing indicates potential issues with Transcode Therapeutics' continued listing on a stock exchange, which could significantly impact its stock price and investor confidence.

Risk Assessment

Risk Level: high — A notice of delisting or failure to meet listing standards poses a significant risk to the company's ability to remain publicly traded.

Key Players & Entities

• Transcode Therapeutics, Inc. (company) — Registrant
• September 23, 2024 (date) — Earliest event reported
• September 27, 2024 (date) — Date of report
• Delaware (jurisdiction) — State of incorporation
• Boston, Massachusetts (location) — Principal executive offices

FAQ

Key Financial Figures

• $0.0001 — registered Common Stock, par value $0.0001 per share RNAZ The Nasdaq Capital M
• $1.00 — intained a minimum closing bid price of $1.00 per share (the "Minimum Bid Price Requi
• $2,500,000 — intain stockholders' equity of at least $2,500,000 (the "Stockholders' Equity Requirement"
• $0.30 — total shares outstanding at a price of $0.30 per share (the "Offering"), a 62% disco
• $0.7925 — a 62% discount to the Minimum Price of $0.7925. The Offering was previously disclosed

Filing Documents

• tm2424982d1_8k.htm (8-K) — 30KB
• 0001104659-24-103706.txt ( ) — 203KB
• rnaz-20240923.xsd (EX-101.SCH) — 3KB
• rnaz-20240923_lab.xml (EX-101.LAB) — 33KB
• rnaz-20240923_pre.xml (EX-101.PRE) — 22KB
• tm2424982d1_8k_htm.xml (XML) — 4KB

01

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. Prior Deficiency Letters As previously disclosed, on August 13, 2024, TransCode Therapeutics, Inc., a Delaware corporation, (the "Company") announced that they had received a letter (the "Minimum Bid Price Deficiency Letter") from the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that, for the 30 consecutive business day period from July 1 through August 12, 2024, the Company's common stock had not maintained a minimum closing bid price of $1.00 per share (the "Minimum Bid Price Requirement") required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2). Normally, a company would be afforded a 180-calendar day period to demonstrate compliance with the Minimum Bid Price Requirement. However, pursuant to Listing Rule 5810(c)(3)(A)(iv), the Company is not eligible for any compliance period specified in Rule 5810(c)(3)(A) because the Company effected two reverse stock splits over the prior two-year period with a cumulative ratio of more than 250 shares to one. Separate from and in addition to the Minimum Bid Price Deficiency Letter, as previously disclosed, on August 15, 2024, the Company received a letter (the "Stockholders' Equity Requirement Deficiency Letter" and together with the Minimum Bid Price Deficiency Letter, the "Prior Deficiency Letters") from the Staff of Nasdaq notifying the Company that it was not in compliance with the minimum stockholders' equity requirement for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1) requires companies listed on The Nasdaq Capital Market to maintain stockholders' equity of at least $2,500,000 (the "Stockholders' Equity Requirement"). The Stockholders' Equity Requirement Deficiency Letter stated that the Company's Stockholders' Equity Requirement Deficiency serves as an additi

View Full Filing

View this 8-K filing on SEC EDGAR